comparemela.com

Latest Breaking News On - Davidw meline - Page 1 : comparemela.com

Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down to $1.82

Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $1.82, but opened at $1.78. Pacific Biosciences of California shares last traded at $1.84, with a volume of 2,907,306 shares changing hands. Wall Street Analysts Forecast Growth Several research analysts have […]

California
United-states
Pacific-biosciences
Piper-sandler
Davidw-meline
Interchange-capital-partners
California-inc
Nasdaq
Barclays
Cetera-advisors
Axxcess-wealth-management
Kennedy-capital-management

Decheng Capital LLC Invests $28.85 Million in Pacific Biosciences of California, Inc. (NASDAQ:PACB)

Decheng Capital LLC Invests $28.85 Million in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

California
United-states
Davidw-meline
Pacific-biosciences
Nasdaq
Decheng-capital
Quest-partners
Edmond-de-rothschild-holding
Goldman-sachs-group
Hsbc-holdings
Dynamic-technology-lab-private-ltd
Us-bancorp

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) have been given a consensus rating of “Moderate Buy” by the fifteen research firms that are covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average […]

California
United-states
Sanfordc-bernstein
Davidw-meline
Pacific-biosciences
Piper-sandler
Nasdaq
Moody-aldrich-partners
Victory-capital-management-inc
Morgan-stanley
Barclays
Scotiabank

Pacific Biosciences of California (NASDAQ:PACB) PT Lowered to $4.00

Pacific Biosciences of California (NASDAQ:PACB – Free Report) had its price objective lowered by Morgan Stanley from $10.00 to $4.00 in a research report report published on Wednesday morning, Benzinga reports. The brokerage currently has an equal weight rating on the biotechnology company’s stock. A number of other analysts have also recently weighed in on […]

California
United-states
Oene-mark-van
Piper-sandler
Pacific-biosciences
Davidw-meline
Wealth-partners
Headlands-technologies
Goldman-sachs-group
Barclays
Kayne-anderson-rudnick-investment-management
California-inc

Pacific Biosciences of California (NASDAQ:PACB) Price Target Cut to $4.00 by Analysts at Morgan Stanley

Pacific Biosciences of California (NASDAQ:PACB – Free Report) had its target price decreased by Morgan Stanley from $10.00 to $4.00 in a research note issued to investors on Wednesday morning, Benzinga reports. Morgan Stanley currently has an equal weight rating on the biotechnology company’s stock. PACB has been the subject of a number of other […]

California
United-states
Davidw-meline
Pacific-biosciences
Piper-sandler
Oene-mark-van
Decheng-capital
California-inc
Edmond-de-rothschild-holding
Securities-exchange-commission
Jpmorgan-chase-co
Morgan-stanley

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.